Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.49 USD

74.49
1,733,033

+0.71 (0.96%)

Updated Aug 19, 2024 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals

Intercept (ICPT) Gains on Earnings and Revenue Beat in Q3

by Zacks Equity Research

Intercept's (ICPT) revenues beat estimates, owing to strong Ocaliva sales in the third quarter of 2018.

    Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal

    by Zacks Equity Research

    Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

    Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag

    by Zacks Equity Research

    Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.

    John Blank headshot

    Can the Strong Economy Save the Stock Market?

    by John Blank

    The U.S. economy is the MOST important fundamental.

    Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Gilead Sciences (GILD) closed at $70.90, marking a +1.66% move from the previous day.

    Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2

    by Zacks Equity Research

    Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.

    The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers (Revised)

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers

    Mark Vickery headshot

    Top Analyst Reports for Johnson & Johnson, UnitedHealth, AT&T & Intel

    by Mark Vickery

    Today's Research Daily features new research reports on 17 major stocks, including Johnson & Johnson (JNJ), UnitedHealth (UNH), AT&T (T) and Intel (INTC).

    Gilead (GILD) Beats on Q3 Earnings & Sales, Updates View

    by Zacks Equity Research

    Gilead's (GILD) third-quarter results beat estimates. However, persistent decline in HCV sales is disappointing.

    Mark Vickery headshot

    New Batch of Q3 Earnings: AMZN, GOOGL, INTC & More

    by Mark Vickery

    Big afternoon of new quarterly earnings releases after the bell today, with some of the world's largest technology firms hitting the tape.

    Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates

    by Zacks Equity Research

    Gilead (GILD) delivered earnings and revenue surprises of 10.84% and 2.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

    Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Vertex' (VRTX) Q3 gains on earnings and revenue beat with demand for its CF products rising high.

    Bristol-Myers (BMY) Beats on Q3 Earnings, Raises EPS View

    by Zacks Equity Research

    Bristol-Myers (BMY) beats earnings estimates in the third quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.

    Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up

    by Zacks Equity Research

    Sarepta (SRPT) misses estimates on both counts in third-quarter 2018. However, Exondys 51 performs well on strong demand.

    Sweta Killa headshot

    Healthcare ETFs to Buy Ahead of Q3 Earnings

    by Sweta Killa

    The positive estimate revisions suggest continued outperformance for the healthcare ETFs.

    Alexion's (ALXN) Earnings Beat Estimates in Q3, Guidance Up

    by Zacks Equity Research

    Alexion (ALXN) beats earnings estimates and marginally misses sales estimates in the third quarter of 2018. The company also inks a deal to acquire Syntimmune for $1.2 billion.

    Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG

    by Zacks Equity Research

    Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.

    Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook

    by Zacks Equity Research

    Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.

    The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers

    Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3?

    by Zacks Equity Research

    Gilead Sciences (GILD) is scheduled to report third-quarter results on Oct 25. We expect investors to focus on the strong HIV franchise and other pipeline updates.

    John Blank headshot

    Earnings Keep Pouring In: Global Week Ahead

    by John Blank

    So far, almost 90% of the firms have beaten analysts' earnings expectations. About 70% have beaten revenue expectations. This week, 156 S&P 500 firms release earnings.

    Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Gilead Sciences (GILD) closed at $74.17, marking a -1.92% move from the previous day.

    Gilead Sciences (GILD) Q3 Earnings Preview: What to Expect

    by Zacks Equity Research

    Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Gilead Sciences (GILD) closed at $73.59, marking a +1.5% move from the previous day.